Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda
By Rob Curran
Lava Therapeutics shares surged after the biotech company said one of its product candidates would be tested on prostate-cancer patients in combination with Merck's blockbuster Keytruda drug.
The Dutch biopharmaceutical firm said the LAVA-1207 drug will be tested in combination with Keytruda on patients with therapy refractory metastatic castration-resistant prostate cancer, a particularly severe form of the disease.
Like Keytruda, Lava's suite of Gammabody drugs use an immunotherapy approach to target cancer cells. Merck will supply the Keytruda doses for patients in Lava's ongoing early-stage Phase 1/2a clinical trial of LAVA-1207, with the combination set to begin in the first half of this year.
Shares of Lava rose 32% to $2.06.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 25, 2024 07:52 ET (12:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy